Plasma cholesterol and risk for late-onset Alzheimer's disease

被引:0
|
作者
Cedazo-Minguez, Angel [1 ]
Ismail, Muhammad-Al-Mustafa [1 ]
Mateos, Laura [1 ]
机构
[1] Karolinska Inst, Alzheimers Dis Res Ctr, Novum, Dept Neurobiol Care Sci & Soc, SE-14186 Stockholm, Sweden
关键词
Alzheimer's disease; cholesterol; cognitive decline; late onset; risk factors; COGNITIVE DECLINE; APOLIPOPROTEIN-E; DEMENTIA; OXYSTEROLS; LIPIDS;
D O I
10.1586/ERN.11.36
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Alzheimer's disease (AD), the most common cause of dementia, is a progressive neurodegenerative disorder affecting millions of people worldwide. AD has a multifactorial origin, resulting from an interaction between genetic susceptibility and environmental risk factors. Genetic, epidemiological, experimental and clinical data strongly suggest that the metabolism of cholesterol has an important role in AD pathogenesis. Several studies have demonstrated that high concentrations of serum cholesterol increase the risk of AD. Statins, drugs that reduce cholesterol levels, have been investigated as a possible treatment for AD. However, the literature is not exempt of contradictory results. In this article, we review a recent article by Reitz et al. demonstrating that higher levels of high-density lipoprotein cholesterol, total cholesterol and non-high-density lipoprotein cholesterol are associated with lower risk of AD. In addition, we discuss the current state of knowledge regarding the relationship between plasma cholesterol and AD, stressing the need for understanding the molecular mechanisms behind this association.
引用
收藏
页码:495 / 498
页数:4
相关论文
共 50 条
  • [41] Association Study of Late-Onset Alzheimer's Disease Risk Variants and Memory Decline
    Carrasquillo, Minerva
    Crook, Julia
    Pedraza, Otto
    Pankratz, Vernon
    Allen, Mariet
    Thuy Nguyen
    Malphrus, Kimberly
    Ma, Li
    Bisceglio, Gina
    Roberts, Rosebud
    Lucas, John
    Ivnik, Robert
    Machulda, Mary
    Graff-Radford, Neill
    Petersen, Ronald
    Younkin, Steven
    Taner, Nilufer
    NEUROLOGY, 2013, 80
  • [43] APOE -: 491 promoter polymorphism is a risk factor for late-onset Alzheimer's disease
    Casadei, VM
    Ferri, C
    Veglia, F
    Gavazzi, A
    Salani, G
    Cattaneo, M
    Sorbi, S
    Annoni, G
    Licastro, F
    Mariani, C
    Franceschi, M
    Grimaldi, LME
    NEUROLOGY, 1999, 53 (08) : 1888 - 1889
  • [44] Alzheimer's disease murine models: focus on late-onset disease
    Potenza, M. A.
    Nacci, C.
    Carratu, M. R.
    DRUGS OF THE FUTURE, 2020, 45 (02) : 109 - 117
  • [45] Search for late-onset familial Alzheimer's disease genes
    Schellenberg, GD
    Yu, CE
    Steinbart, EJ
    Bird, TD
    Wijsman, EM
    Daw, EW
    Payami, H
    Conlon, EM
    Nochlin, D
    NEUROBIOLOGY OF AGING, 2002, 23 (01) : S10 - S10
  • [46] The 'eye test' in recognition of late-onset Alzheimer's disease
    Caputo, L
    Casartelli, M
    Perrone, C
    Santori, M
    Annoni, G
    Vergani, C
    ARCHIVES OF GERONTOLOGY AND GERIATRICS, 1998, 27 (02) : 171 - 177
  • [47] α2-macroglobulin in late-onset Alzheimer's disease
    Kovacs, DM
    EXPERIMENTAL GERONTOLOGY, 2000, 35 (04) : 473 - 479
  • [48] Neuropathology of preclinical and clinical late-onset Alzheimer's disease
    Troncoso, JC
    Cataldo, AM
    Nixon, RA
    Barnett, JL
    Lee, MK
    Checler, F
    Fowler, DR
    Smialek, JE
    Crain, B
    Martin, LJ
    Kawas, CH
    ANNALS OF NEUROLOGY, 1998, 43 (05) : 673 - 676
  • [49] Early and late-onset Alzheimer's disease: What are the differences?
    Awada, Adnan A.
    JOURNAL OF NEUROSCIENCES IN RURAL PRACTICE, 2015, 6 (03) : 455 - +
  • [50] Assessment of the genetic variance of late-onset Alzheimer's disease
    Ridge, Perry G.
    Hoyt, Kaitlyn B.
    Boehme, Kevin
    Mukherjee, Shubhabrata
    Crane, Paul K.
    Haines, Jonathan L.
    Mayeux, Richard
    Farrer, Lindsay A.
    Pericak-Vance, Margaret A.
    Schellenberg, Gerard D.
    Kauwe, John S. K.
    NEUROBIOLOGY OF AGING, 2016, 41